Navigation Links
QuantRx Biomedical Corporation Provides Corporate Update

PORTLAND, Ore., July 14, 2011 /PRNewswire/ -- QuantRx® Biomedical Corporation (OTCQB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms, is pleased to announce that following the successful resolution and full settlement of all matters related to the QN Joint Venture as disclosed in a Form 8-K filed with the SEC on July 8, 2011, the Company is currently implementing a go to market strategy for its market ready over-the-counter (OTC) healthcare products.

Further, the Company plans to initiate a clinical study to confirm an innovative, and potentially practice changing, approach to fetal genomic diagnostics using its patented PadKit technology. These clinical investigations will be done in collaboration with GMSBIOTECH, with initial data anticipated to be generated prior to year end.

Dr. Shalom Hirschman, Chairman and CEO, stated, "The company is developing strategic plans to bring products to market as quickly as possible. Our OTC pads for daily feminine hygiene and intergluteal pads for the temporary relief of hemorrhoids will be the focus of the initial commercialization effort."

Further, Dr, William Fleming, Chief Scientific Officer, stated, "We are committed to building shareholder value by capitalizing on our innovative patented diagnostic technologies, particularly our genomic-based diagnostic technology targeting the monitoring of recurring cancers and serious fetal genomic disease and health conditions."

About QuantRx Biomedical

QuantRx Biomedical Corporation (OTCQB: QTXB) is focused on the development and commercialization of innovative over-the-counter and genomic products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms leveraging a vast portfolio of intellectual property, QuantRx's mission is to introduce products for use by its medical laboratory and consumers that deliver more accurate, reliable, and cost-effective diagnoses which result in improved patient care and a reduction in overall healthcare costs. The Company's technology portfolio, with more than a dozen patents, patents pending and licensed patents, includes: PAD technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and significant investments in genome-based diagnostic chips for the laboratory and healthcare professional markets, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company's need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Dr. William Fleming
Chief Scientific Officer
QuantRx Biomedical Corporation
Tel. 305-740-4465

SOURCE QuantRx Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products
2. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
3. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
4. NCIIA Funds University Biomedical Engineering Teams at BMEidea Awards
5. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
6. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
7. R. Lindholm Named to Crux Biomedical Board
8. FCC Approval of Finite Element Method for Biomedical Transmitters Puts ANSYS Software in the Spotlight
9. Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. BioMedical Enterprises, Inc. (BME) Introduces the HammerLock™ Shape Memory Device for Hammertoes.
Post Your Comments:
(Date:11/27/2015)... 27, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), ... biopharmaceuticals company UCB S.A. (Euronext: UCB). ... acquired KU from UCB for total consideration of ... a customary working capital adjustment, a deduction of ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively for ... to wipes with blur & drop shadow options. Utilize the controls in the ... clip to the next with TransPack's easily customizable styles. , TransPack Volume ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation ... more than 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. ... of corporate, industrial, manufacturing and government workers and organizational leaders that are introduced ...
(Date:11/29/2015)... Petersburg, FL (PRWEB) , ... November 30, 2015 ... ... are available today from the new company, Sublime Beauty NATURALS®. All products are ... and natural products, like essential oils, organic facial serums and USDA Certified Organic ...
(Date:11/29/2015)... ... November 29, 2015 , ... Khanna Vision Institute based in Los Angeles, announced ... November 25th 2015. Peer Certification by the Board is done so the public knows ... is first obtained after the completion of three years of training or Residency in ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing service for ... featured apartment community: Epic. In showcasing this featured apartment community in San Jose, Key ... rental market to efficiently find housing suitable to their needs by showcasing quality housing. ...
Breaking Medicine News(10 mins):